Summary:
A Phase 3b Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating Safety and Efficacy of XXX Compared to Placebo in Adult Subjects with Moderate to Severe Plaque Psoriasis with Palmoplantar (Non-Pustular) Involvement (PPPsO)
Qualified Participants Must:
18 year of age or older
Chronic Psoriasis on palms and soles
Previously inadequately controlled disease by topicals, phototherapy, and/or systemic treatments
Qualified Participants May Receive:
Compensation of 50$ per visit for a total of 350$.
All laboratories and assessments at no cost.
Investigational product or placebo during the first 16 weeks. After week 16 the patients will receive the investigational product until the end of the study at week 52.
The investigational product is a medicine already approved in the market.